Metabolic activation of the anti-hepatitis C virus nucleotide prodrug PSI-352938

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3767-3775

  Niu, Congrong ^a,c   Tolstykh, Tatiana ^a,d   Bao, Haiying ^a,c   Park, Yeojin ^c   Babusis, Darius ^c   Lam, Angela M ^a,c   Bansal, Shalini ^a,c   Du, Jinfa ^a,c   Chang, Wonsuk ^a,c   Reddy, P Ganapati ^a,c   Zhang, Hai Ren ^a,c   Woolley, Joseph ^a,c   Wang, Li Quan ^b   Chao, Piyun B ^b   Ray, Adrian S ^c   Otto, Michael J ^a   Sofia, Michael J ^a,c   Furman, Phillip A ^a   Murakamic, Eisuke ^c  

^a PHARMASSET INC   (United States)

^b XENOBIOTIC LABORATORIES INC   (United States)

^c GILEAD SCIENCES   (United States)

^d Sanofi Aventis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DEAMINASE LIKE PROTEIN 1; GUANYLATE KINASE 1; NUCLEIC ACID BASE; NUCLEOSIDE DIPHOSPHATE KINASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 11A4; PHOSPHODIESTERASE 2A1; PHOSPHODIESTERASE 5A; PHOSPHODIESTERASE 9A; PHOSPHODIESTERASE INHIBITOR; PHOSPHOTRANSFERASE; PROTEIN; PSI 352666; PSI 352938; RNA DIRECTED RNA POLYMERASE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG MECHANISM; DRUG METABOLISM; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIVER CELL; METABOLITE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPLICON; VIRUS CELL INTERACTION;

ANTIVIRAL AGENTS; CELLS, CULTURED; CYCLIC P-OXIDES; CYTOCHROME P-450 CYP3A; GUANYLATE KINASE; HEPACIVIRUS; HEPATOCYTES; HUMANS; NUCLEOSIDE-DIPHOSPHATE KINASE; NUCLEOSIDES; PHOSPHORIC DIESTER HYDROLASES;

EID: 84862518079     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00530-12     Document Type: Article

References (29)

1. Alter HJ. 2005. HCV natural history: the retrospective and prospective in perspective. J. Hepatol. 43:550 -552.
2. Bender AT, Beavo JA. 2006. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58:488-520.
3. Bianchi V, Spychala J. 2003. Mammalian 5′-nucleotidases. J. Biol. Chem. 278:46195-46198.
4. Clark JL, et al. 2006. Synthesis and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication. Bioorg. Med. Chem. Lett. 16:1712-1715.
5. De Clercq E. 2004. Antiviral drugs in current clinical use. J. Clin. Virol. 30:115-133.
6. Eldrup AB, et al. 2004. Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J. Med. Chem. 47:2283-2295.
7. Erion MD, et al. 2004. Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J. Am. Chem. Soc. 126:5154-5163.
8. Erion MD, et al. 2005. Liver-targeted drug delivery using HepDirect prodrugs. J. Pharmacol. Exp. Ther. 312:554-560.
9. Francis SH, Turko IV, Corbin JD. 2001. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65:1-52.
10. Furman PA, et al. 2011. Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661. Antiviral Res. 91:120-132.
11. Gane E, et al. 2009. Combination therapy with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor in HCV: safety, pharmacokinetics, and virologic results from INFORM-1, abstr 193. Abstr. 60th Annu. Meet. Am. Assoc. Study Liver Dis., Boston, MA.
12. Gunic E, et al. 2007. Cyclic monophosphate prodrugs of base-modified 2′-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication. Bioorg. Med. Chem. Lett. 17:2452-2455.
13. Guo L, et al. 2011. Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab. Dispos. 39:528-538.
14. Ipata PL, Tozzi MG. 2006. Recent advances in structure and function of cytosolic IMP-GMP specific 5′-nucleotidase II (cN-II). Purinergic Signal. 2:669-675.
15. Ishii K, et al. 1999. Expression of hepatitis C virus NS5B protein: characterization of its RNA polymerase activity and RNA binding. Hepatology 29:1227-1235.
16. Korth M, Engels J. 1979. The effects of adenosine-and guanosine 3′,5′-phosphoric acid benzyl esters on guinea-pig ventricular myocardium. Naunyn Schmiedebergs Arch. Pharmacol. 310:103-111.
17. Lalezari J, et al. 2008. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500mg BID for 28 days, abstr 66. Abstr. 43rd Annu. Meet. Eur. Assoc. Study Liver, Milan, Italy.
18. Lam AM, et al. 2011. Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2′-deoxy- 2′-α-fluoro-2′-β-C-methylguanosine. Antimicrob. Agents Chemother. 55:2566-2575.
19. Lawitz E, et al. 2009. Potent antiviral activity observed with PSI-7851, a novel nucleotide polymerase inhibitor for HCV, following multiple ascending oral doses for 3 days in patients with chronicHCVinfection, abstr 103. HEP DART, Kohala Coast, HI, 6 to 10 December 2010.
20. Lohmann V, Korner F, Herian U, Bartenschlager R. 1997. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J. Virol. 71:8416-8428.
21. Lohmann V, Roos A, Korner F, Koch JO, Bartenschlager R. 1998. Biochemical and kinetic analyses of NS5B RNA-dependentRNApolymerase of the hepatitis C virus. Virology 249:108-118.
22. Migliaccio G, et al. 2003. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278:49164-49170.
23. Murakami E, et al. 2011. Adenosine deaminase-like protein 1 (ADAL1): characterization and substrate specificity in the hydrolysis of N(6)-or O(6)-substituted purine or 2-aminopurine nucleoside monophosphates. J. Med. Chem. 54:5902-5914.
24. Murakami E, et al. 2010. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J. Biol. Chem. 285:34337-34347.
25. Paine MF, et al. 2006. The human intestinal cytochrome P450 "pie." Drug Metab. Dispos. 34:880-886.
26. Reddy PG, et al. 2010. 2′-Deoxy-2′-alpha-fluoro-2′- beta-C-methyl 3′,5′-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938. Bioorg. Med. Chem. Lett. 20:7376-7380.
27. Reddy R, et al. 2007. Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy, abstr LB9. Abstr. 58th Annu. Meet. Am. Assoc. Study Liver Dis., Boston, MA.
28. Resta R, Yamashita Y, Thompson LF. 1998. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol. Rev. 161:95-109.
29. Yamashita T, et al. 1998. RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region. J. Biol. Chem. 273:15479-15486.